Sohel Parvez Haque / shutterstock.com
26 October 2016Americas

Otsuka sues Zydus over Abilify

Japan-based Otsuka Pharmaceuticals has filed a complaint against US-based Zydus Pharmaceuticals for allegedly infringing a patent directed to the drug Abilify (aripiprazole).

Abilify is an atypical antipsychotic which is primarily used in the treatment of schizophrenia and bipolar disorder.

The case, filed on Friday, October 21 in the US District Court for the District of New Jersey, came after Zydus filed two Abbreviated New Drug Applications (ANDAs) with the Food and Drug Administration (FDA).

Zydus is seeking approval to manufacture a generic version of Abilify before the US patent involved, number 9,359,302, expires in September 2022.

Otsuka has asked the court to enter a judgment that Zydus has infringed at least one claim of the ‘302 patent by seeking ANDA approval from the FDA.

The Japanese company has also asked the court to award it costs and expenses for bringing the case to court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk